Navidea Announces Lymphoseek® Presentations at Upcoming Medical Conferences
April 15 2015 - 7:30AM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today
announced that Lymphoseek® (technetium Tc 99m tilmanocept)
injection data are scheduled for presentations at the following
conferences: American Society of Breast Surgeons 16th Annual
Meeting in Orlando, FL, and 2015 American Head & Neck Society
Annual Meeting & Translational Research Meeting, held during
the Combined Otolaryngology Spring Meetings (COSM) in Boston, MA.
Details of the presentations are listed below.
2015 American Head & Neck Society
Annual Meeting & Translational Research Meeting, held during
the Combined Otolaryngology Spring Meetings (COSM)
April 21 - 23, 2015 Boston, MA
Session Type:
Oral
Date:
April 22, 2015
Title:
Pivotal Phase 3 Trial Results of
99mTc-Tilmanocept in Sentinel Lymph Node Detection in Oral Cancer
Patients: Comparison of “Same Day” vs “Next Day” imaging and
diagnostic efficacy in floor of mouth disease
Authors:
Stephen Y. Lai1*, Amit Agrawal2, Frank
Civantos3
1M.D. Anderson Cancer Center, Houston, TX;
2The Ohio State University Wexner Medical Center, Columbus, OH;
3University of Miami Hospital, Miami, FL
*Presenter
American Society of Breast Surgeons 16th Annual
Meeting
April 29 – May 3, 2015 Orlando, FL
Session Type:
Oral
Date:
May 2, 2015
Title:
Sentinel node mapping with
99mTc-tilmanocept: clinical trial results and follow-up data show
consistent performance across studies and tumor types
Authors:
Anne Wallace1, Jennifer Baker2*
1Plastic Surgery, University of California
- San Diego, San Diego, CA; 2Department of Surgery, University of
California - San Diego, San Diego, CA
*Presenter
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics, therapeutics and
radiopharmaceutical agents. Navidea is developing multiple
precision-targeted products and platforms including Manocept™,
NAV4694, and NAV5001, to help identify the sites and pathways of
undetected disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global
partnering and commercialization efforts. For more information,
please visit www.navidea.com.
Navidea BiopharmaceuticalsInvestorsTom Baker,
617-532-0624tbaker@navidea.comorMediaSharon Correia, 978-655-2686Associate
Director, Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024